394 A phase I dose escalation and pharmacological study of the novel class I selective histone deacetylase inhibitor CHR-3996, in patients with advanced or treatment refractory solid tumours

2010 ◽  
Vol 8 (7) ◽  
pp. 125
Author(s):  
F. Eskens ◽  
L. van Doorn ◽  
D. Papadatos-Pastos ◽  
P. Debnam ◽  
M. Tall ◽  
...  
Keyword(s):  
Phase I ◽  
Histone Deacetylase ◽  
Dose Escalation ◽  
Histone Deacetylase Inhibitor ◽  
Pharmacological Study ◽  
Solid Tumours ◽  
Class I ◽  
The Novel ◽  
Deacetylase Inhibitor ◽  
Treatment Refractory

scholarly journals A Phase I Pharmacokinetic and Pharmacodynamic Study of CHR-3996, an Oral Class I Selective Histone Deacetylase Inhibitor in Refractory Solid Tumors

2012 ◽  
Vol 18 (9) ◽  
pp. 2687-2694 ◽  
Author(s):  
Udai Banerji ◽  
Leni van Doorn ◽  
Dionysis Papadatos-Pastos ◽  
Rebecca Kristeleit ◽  
Phillip Debnam ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Histone Deacetylase ◽  
Histone Deacetylase Inhibitor ◽  
Class I ◽  
Deacetylase Inhibitor ◽  
Pharmacodynamic Study

Phase I study of domatinostat (4 SC ‐202), a class I histone deacetylase inhibitor in patients with advanced hematological malignancies

2019 ◽  
Vol 102 (2) ◽  
pp. 163-173 ◽  
Author(s):  
Bastian Tresckow ◽  
Cyrus Sayehli ◽  
Walter E. Aulitzky ◽  
Maria‐Elisabeth Goebeler ◽  
Matthias Schwab ◽  
...  
Keyword(s):  
Phase I ◽  
Histone Deacetylase ◽  
Histone Deacetylase Inhibitor ◽  
Phase I Study ◽  
Hematological Malignancies ◽  
Class I ◽  
Deacetylase Inhibitor
Sign in / Sign up

Export Citation Format

Share Document